198 related articles for article (PubMed ID: 30499396)
1. An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer.
Majhi M; Ali MA; Limaye A; Sinha K; Bairagi P; Chouksey M; Shukla R; Kanwar N; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(27):2355-2366. PubMed ID: 30499396
[TBL] [Abstract][Full Text] [Related]
2. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
3. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Virtual Screening for Defeating Drug Resistant Form of EGFR Protein.
Sharifi A; Bagherzadeh K; Golestanian S; Amanlou M
Comb Chem High Throughput Screen; 2016; 19(3):228-37. PubMed ID: 26768339
[TBL] [Abstract][Full Text] [Related]
5. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
[TBL] [Abstract][Full Text] [Related]
7.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
8. Identification and Pharmacological Analysis of High Efficacy Small Molecule Inhibitors of EGF-EGFR Interactions in Clinical Treatment of Non-Small Cell Lung Carcinoma: a Computational Approach.
Gudala S; Khan U; Kanungo N; Bandaru S; Hussain T; Parihar M; Nayarisseri A; Mundluru HP
Asian Pac J Cancer Prev; 2015; 16(18):8191-6. PubMed ID: 26745059
[TBL] [Abstract][Full Text] [Related]
9. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
11. Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.
Abdelgawad MA; Musa A; Almalki AH; Alzarea SI; Mostafa EM; Hegazy MM; Mostafa-Hedeab G; Ghoneim MM; Parambi DGT; Bakr RB; Al-Muaikel NS; Alanazi AS; Alharbi M; Ahmad W; Bukhari SNA; Al-Sanea MM
Drug Des Devel Ther; 2021; 15():2325-2337. PubMed ID: 34103896
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
13. The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.
Mohyeldin MM; Akl MR; Siddique AB; Hassan HM; El Sayed KA
Biochem Pharmacol; 2017 Feb; 126():51-68. PubMed ID: 27940262
[TBL] [Abstract][Full Text] [Related]
14. Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design.
Park H; Jung HY; Mah S; Hong S
Angew Chem Int Ed Engl; 2017 Jun; 56(26):7634-7638. PubMed ID: 28493467
[TBL] [Abstract][Full Text] [Related]
15. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
16. Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants.
García-Godoy MJ; López-Camacho E; García-Nieto J; Nebro AJ; Aldana-Montes JF
Molecules; 2016 Nov; 21(11):. PubMed ID: 27869781
[TBL] [Abstract][Full Text] [Related]
17. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
Sabbah DA; Hajjo R; Sweidan K
Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
[TBL] [Abstract][Full Text] [Related]
18. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
[TBL] [Abstract][Full Text] [Related]
19. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
[TBL] [Abstract][Full Text] [Related]
20. In silico screening of chalcone derivatives as promising EGFR-TK inhibitors for the clinical treatment of cancer.
Mathpal S; Joshi T; Sharma P; Maiti P; Nand M; Pande V; Chandra S
3 Biotech; 2024 Jan; 14(1):18. PubMed ID: 38130684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]